Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KCNQ3 | O43525 | 13/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 13/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 9/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 9/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317019 | 1.00 | L3MBTL1 (0.60) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL8507258 | 0.81 | L3MBTL1 (0.62) | L3MBTL1KCNQ3KCNQ2RAB9ANPC1 | |
| SCHEMBL5648687 | 0.81 | L3MBTL1 (0.62) | L3MBTL1RAB9ANPC1PAX8KLF5 | |
| SCHEMBL5629234 | 0.80 | KCNQ3 (0.60) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14064670 | 0.80 | L3MBTL1 (0.55) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL31378805 | 0.80 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL535403 | 0.80 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL30568974 | 0.80 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL6361424 | 0.80 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL14329107 | 0.79 | L3MBTL1 (0.60) | L3MBTL1RAB9ANPC1PAX8KLF5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8664397-B2 | Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664397-B2 | Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20080293761-A1 | Pyrrolopyridine-2-Carboxylic Acid Amide Derivative Useful as Inhibitor of Glycogen Phosphorylase | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293761-A1 | Pyrrolopyridine-2-Carboxylic Acid Amide Derivative Useful as Inhibitor of Glycogen Phosphorylase | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| CN-1867334-A | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-22 | — | — | CN | disclosed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
| US-4536208-A | Certain naphthyridine diether compounds and their herbicidal use | THE DOW CHEMICAL COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| US-4533381-A | Naphthyridinyloxy(or thio)phenoxy propanoic acids, derivatives thereof and methods of herbicidal use | THE DOW CHEMICAL COMPANY (US) | 1985-08-06 | — | — | US | disclosed |
| US-4472193-A | Naphthyridinyloxy(or thio)phenoxy propanoic acids, derivatives thereof and methods of herbicidal use | THE DOW CHEMICAL COMPANY (US) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | L3MBTL1 788/4885KCNQ3 2135/4885KCNQ2 2146/4885 |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | L3MBTL1 2008/4885KCNQ3 1000/4885KCNQ2 1163/4885 |
| US-20080293761-A1 | Pyrrolopyridine-2-Carboxylic Acid Amide Derivative Useful as Inhibitor of Glycogen Phosphorylase | PYGM, PYGL, PGD | L3MBTL1 4495/4885KCNQ3 4098/4885KCNQ2 3364/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | L3MBTL1 1776/4885KCNQ3 47/4885KCNQ2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.